Affinium Pharmaceuticals

15 articles about Affinium Pharmaceuticals

• Debiopharm To Acquire Affinium Pharmaceuticals's Antibiotic Clinical Assets And Platform To Identify And Develop Targeted Antibiotics

  2/10/2014

• Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation By The FDA For AFN-1252 And Completion Of Dosing Of AFN-1720 Phase 1 Trial

  11/12/2013

• Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round

  9/5/2013

• Positive Results From Affinium Pharmaceuticals' Phase 2a Clinical Trial of AFN-1252 in ABSSSI

  3/21/2013

• Affinium Pharmaceuticals Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections

  8/7/2012

• Affinium Pharmaceuticals Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial

  5/2/2011

• Affinium Pharmaceuticals to Present at Super Bugs - Super Drugs Conference in London, UK

  3/15/2011

• Affinium Pharmaceuticals Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252, its Novel Anti-staphylococcal Antibiotic

  4/12/2010

• GlaxoSmithKline, Novartis AG, Pfizer Inc., AstraZeneca AB, Albert Einstein College of Medicine, Centers for Disease Control and Prevention (CDC), And AstraZeneca AB Explore Advances in Anti-Infective Drug Development

  12/9/2009

• Affinium Pharmaceuticals Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic

  3/4/2008

• Affinium Pharmaceuticals Welcomes Dr. Barry Hafkin as Chief Medical Officer

  4/2/2007

• Affinium Pharmaceuticals Closes US$18 Million Series A to Advance Clinical Development of Novel Antibacterial Compound

  3/26/2007

• Accium BioSciences, Inc. To Provide Microdosing Services To Affinium Pharmaceuticals In Support Of A Biodefense Research Contract

  2/12/2007

• Affinium Pharmaceuticals Awarded US$4.8 Million Biodefense Research Contract By United States Department Of Defense/DTRA

  1/4/2007

• Blueprint Collaborates To Provide Access To Bacterial Interaction Networks

  5/20/2005